A small percentage of patients were administered drugs from all medication groups: hospice 17%, community 13% and hospital 4%. The number of patients administered drugs from each category varied across care setting but more patients required benzodiazepines and opioids compared to anti-secretories or anti-emetics.

Conclusions There are relatively few prescriptions for octreotide despite the audit data coming from a large cancer centre. Prescriptions generally follow the guidelines however documentation of indication and reason for divergence from the guideline needs improving.

Recommendations Consider using standardised documentation for when starting octreotide including indication, other medications concurrently prescribed, dietician involvement and NG tube placement.

Abstracts

196  A CLINICAL AUDIT OF USE OF OCTREOTIDE IN THE MANAGEMENT OF INOPERABLE MALIGNANT BOWEL OBSTRUCTION AT A LARGE CANCER CENTRE

Jennifer Palfrey, Vandana Vora. Guy's and St Thomas' Hospital

Background Octreotide is a somatostatin analogue used to reduce gastric and intestinal secretions therefore helping to improve symptoms of nausea and vomiting. There is mixed evidence for the use of octreotide however in both local guidelines and the Palliative Care Formulary it is considered second line for the treatment of vomiting and managing secretions in malignant bowel obstruction with hyoscine butylbromide as first line.

Objectives 1. To gain insight into the scale of prescribing of octreotide for inoperable malignant bowel obstruction in a tertiary cancer centre.
2. To compare the prescribing practices for octreotide in inoperable malignant bowel obstruction to those outlined in the local and national guidance.

Methods A retrospective audit of the electronic notes and online prescriptions for inpatients prescribed octreotide for inoperable malignant bowel obstruction over a one-year period. A total of 17 patients.

Audit standards:
1. The patient has been prescribed hyoscine butyl bromide prior to being prescribed octreotide.
2. The patient has been started on a dose of octreotide between 300–600 mcg/24hrs.
3. The patient has not been prescribed a dose of octreotide greater than 1500 mcg/24hrs.
4. The patient has a clearly documented reason for the use of octreotide.

Results
- Only 41% patients had hyoscine butyl bromide prescribed prior to being prescribed octreotide.
- 100% patients received the recommended starting dose of octreotide.
- No patients received octreotide received a dose greater than 1500 mcg/24hrs.
- 71% patients had a specific indication documented in the notes.

Aim To assess what is known in the literature regarding the use of subcutaneous furosemide in advanced heart failure, as a foundation for further research.

Background Chronic Heart Failure is a leading cause of morbidity and mortality, and a growing public health problem. If resistance to oral diuretics develops amongst those with end-stage disease, subcutaneous furosemide can be administered for symptom management in community settings, to prevent hospital admission and to honour preferred place of care and death. However, there is a lack of national consensus and use tends to occur in geographical pockets.

Method PubMed, EmCare and HDAS databases were used to look for articles with the key words ‘subcutaneous furosemide’, ‘advanced’, ‘end-stage’, ‘heart failure’, ‘palliative care’ and ‘hospice’. The papers were thematically analysed and a report compiled.

Results 15 articles were identified through database searches, and a further 3 relevant articles through other means. Just 2 papers involved a randomised controlled trial. All studies referred to the efficacy of the drug administered parenterally and several mentioned the research gap. Other areas addressed included side effects, benefits in community settings and economic implications.

Conclusions/My research idea As further research is required, I aim to develop a research project based on gathering evidence of the experience of health professionals and the efficacy of use of subcutaneous furosemide in end stage heart failure patients locally in the West Midlands. I intend to use an online survey tool.

198  NALOXONE USE IN PATIENTS RECEIVING THERAPEUTIC OPIOIDS: ARE WE FOLLOWING THE GUIDANCE?

Paul Selway, Charlotte French. Royal Albert Edward Infirmary, Wigan

Introduction There is clear guidance that naloxone should not be used for patients approaching end of life and should be used at a lower dose and with great caution in those receiving long term therapeutic opioids. After being asked to review a terminally ill patient with a reduced level of consciousness who had received boluses of naloxone and was about to be started on a naloxone infusion, we decided to examine local prescribing practice and assess whether guidelines are being adhered to.
Methods Data regarding naloxone prescribing was obtained for two three-month periods; prior to and following the introduction of a prescribing order set which included guidance on the indications for naloxone use and appropriate doses. The notes of all patients who received naloxone in each time period were reviewed; and only patients prescribed long term opioids for pain were included in the audit. Data collected included age, sex, type and dose of opioid, equivalent doses of oral morphine per day, dose of naloxone administered, stated indication for use, respiratory rate, oxygen saturations and time to death where applicable.

Results Prior to the intervention 15 patients were identified. All of these received inappropriately high doses of naloxone. Following the intervention, the number of patients reduced by more than 50% (n=7), however all patients still received inappropriate doses. Worryingly there were no patients in either time period who had documented evidence of respiratory depression; most clinicians cited reduced level of consciousness as the reason for administering the drug.

Conclusion This intervention may have reduced the number of inappropriate prescriptions of naloxone in this subset of patients. However, more education is required to improve knowledge around the appropriate use of this potentially harmful drug. Future training sessions are planned to include staff from the emergency department and acute medicine.

Background Anaemia is common in palliative care. Treatment of iron deficiency, if present, is recommended to improve symptoms and reduce dependency on blood transfusion. Previously, use of intravenous iron has been limited by the risk of anaphylaxis, however newer preparations have greatly improved safety profiles. Despite this, the feasibility of their use in hospices is unclear.

Methods A policy for administering intravenous iron at Marie Curie Hospice Liverpool was developed as part of a project to improve the targeted treatment of anaemia. Retrospective review of electronic patient and laboratory records was performed for patients receiving the intervention between October 2018 and July 2019. In all cases a single dose of Monofer (iron (III) isomaltoside) was given in keeping with the product literature.

Results 12 infusions were given to 10 patients. 4 were inpatients, the remainder day cases. Mild extravasation occurred in one case, leading to discolouration but no pain. There were no other adverse reactions. 30, 60 and 90-day survival was 92%, 92% and 58% respectively. Baseline haemoglobin was 80 g/L in 6 cases, 80–100 in 3 and >100 in 3. All met recommended criteria for diagnosing iron deficiency in cancer (ferritin <100μg/L and transferrin saturation <20%). Fatigue was documented for all, alongside breathlessness in 4 and bleeding in 2. 6 patients had received transfusions within the previous 3 months. Iron was given alone in 8 cases, none required subsequent transfusion. Transfusion was performed in addition to the iron infusion in 4 cases, 3 requiring further transfusions, although two had apparently decreased frequency to previously.

Conclusion This case series demonstrates the feasibility of using intravenous iron, within its product specification, to treat iron deficiency anaemia in a hospice setting. Research is required to confirm the efficacy and optimum targeting of this approach in palliative care populations.